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Type A Botulinum neurotoxin (BoNT/A), the most potent poison known to mankind, is
produced by Clostridium botulinum type A as a complex with neurotoxin-associated
proteins (NAPs). Currently BoNT/A in puriﬁed and complex forms are both available in
therapeutic and cosmetic applications to treat neuromuscular disorders. Whereas
Xeomin (incobotulinumtoxin A, Merz Pharmaceuticals, Germany) is free from complexing
proteins, Botox (onabotulinumtoxin A, Allergan, USA) contains NAPs, which by them-
selves have no known role in the intracellular biochemical process involved in the
blockade of neurotransmitter release. Since the fate and possible interactions of NAPs with
patient tissues after intramuscular injection are not known, it was the aim of this study to
evaluate the binding of BoNT/A and/or the respective NAPs to cells derived from neuronal
and non-neuronal human tissues, and to further explore neuronal cell responses to
different components of BoNT/A. BoNT/A alone, the complete BoNT/A complex, and the
NAPs alone, all bind to neuronal SH-SY5Y cells. The BoNT/A complex and NAPs additionally
bind to RMS13 skeletal muscle cells, TIB-152 lymphoblasts, Detroit 551 ﬁbroblasts besides
the SH-SY5Y cells. However, no binding to these non-neuronal cells was observed with
pure BoNT/A. Although BoNT/A, both in its puriﬁed and complex forms, bind to SH-SY5Y,
the intracellular responses of the SH-SY5Y cells to these BoNT/A components are not
clearly understood. Examination of inﬂammatory cytokine released from SH-SY5Y cells
revealed that BoNT/A did not increase the release of inﬂammatory cytokines, whereas
exposure to NAPs signiﬁcantly increased release of IL-6, and MCP-1, and exposure to BoNT/
A complex signiﬁcantly increased release of IL-6, MCP-1, IL-8, TNF-a, and RANTES vs.
control, suggesting that different components of BoNT/A complex induce signiﬁcantly
differential host response in human neuronal cells. Results suggest that host response to
different compositions of BoNT/A based therapeutics may play important role in local and
systemic symptoms in patients.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license./A, botulinum neuro-
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Botulinum neurotoxins (BoNTs), the most potent poison
known to mankind (Arnon et al., 2001; Gill, 1982), is
genetically and immunologically classiﬁed into 7 serotypes
A to G (Singh and DasGupta, 1989; Simpson, 2004). And
recently, a new strain IBCA10-7060 was identiﬁed to pro-
duce the eighth serotype BoNT/H from a patient with infantlicense.
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tially on peripheral cholinergic nerve terminals to inhibit
acetylcholine release resulting in ﬂaccid muscle paralysis.
Despite their lethal properties, BoNTs type A and B are used
in medical conditions such as muscle hyperactivity,
neuromuscular disorders, various types of pain, and treat-
ment of wrinkles (Rohrich et al., 2003; Salti and Ghersetich,
2008).
Among all the toxin serotypes produced by Clostridium
botulinum, the duration of type A has the most sustained
action in both laboratory animals or in human beings
(Keller and Neale, 2001; Foran et al., 2003). The BoNT/A
consists of the 150 kDa neurotoxin itself and a set of
neurotoxin associated complexing proteins (NAPs),
comprising hemagglutinins of 17, 23, 33, 48 kDa and a non-
toxin non-hemagglutinin of 138 kDa (Inoue et al., 1996;
Sharma et al., 2003). While the NAPs do not play a role in
toxin-induced blockade of cholinergic neurotransmission,
the presence of NAPs protects BoNTs against proteases of
the GI tract during oral poisoning thus enhancing the oral
toxicity of the neurotoxin signiﬁcantly (Sakaguchi, 1982).
The currently approved therapeutic applications of BoNTs
are by injection into targeted sites, and not via oral intake.
Thus the role and effects of these associated proteins need
to be further investigated. BoNTs, by their bacterial origin
characteristic, are immunogenic. Moreover, the large size of
both the complex and the neurotoxin subunit increases the
chance of an antitoxin response (Critchﬁeld, 2002). It has
been reported that after therapeutic administration of
BoNT/A-based drugs, ﬂu-like symptoms have been re-
ported in 1.7–20% of patients injected with BoNT/A and in
5–55% of those injected with BoNT/B (Baizabal-Carvallo
et al., 2011) Clinical application of BoNTs has also been re-
ported to induce immuno-resistance response from pa-
tients (Benecke, 2012). It is unclear which component of
the drug, if any, may accentuate the immune response or
inﬂammatory process.
Since the fate and possible interactions of NAPs with
patient tissues after intramuscular injection are not known,
it was the aim of this study to evaluate the binding of BoNT/
A and/or the respective NAPs to cells derived from neuronal
and various non-neuronal human cell lines. BoNT/A and,/or
NAPs-induced cytokine release was determined in human
neuroblastoma cell line SH-SY5Y, which has been exten-
sively used as a cellular model to investigate intracellular
mechanisms of drug actions in human neurons (Xie et al.,
2010; Biedler et al., 1978). Our analysis indicates that pure
BoNT/A, BoNT/A complex, and NAPs bind dramatically
differently to cells developed from human neuronal and
non-neuronal tissues, and induce different cytokine release
from the neuronal cell line SH-SY5Y, suggesting a signiﬁ-
cant role of host response upon exposure to different
components of BoNT/A.
2. Materials and methods
2.1. Materials
The 150 kDa BoNT/A holotoxin and 500 kDa BoNT/A
complex were purchased from Metabiologics Inc. (Madi-
son, WI). NAPs were obtained from dissociated BoNT/AComplex as previous established (Sharma et al., 2003). The
NAPs pool was created with DEAE-Sephadex A-50 column
at pH 5.5 (20 mM sodium phosphate buffer) followed by a
ﬁnal ﬂow through the SP-Sephadex C-50 column equili-
brated with the 20 mM sodium phosphate buffer at pH 7.0.
All toxins were produced by a Hall A strain of C. botulinum.
Toxin activities for the holotoxin and the complex were
2.1 107 MLD50/mg and 3.6  107 MLD50/mg, respectively,
according to the manufacturer. The human neuroblastoma
cell line SH-SY5Y, human skeletal muscle cell line RMS13,
Jurkat cell line TIB-152, and human skin ﬁbroblast cell line
Detroit 551 were obtained from American Type Culture
Collection (ATCC, Manassas, VA). Tissue culture media were
ATCC-formulated Eagle’s Minimum Essential Medium
(ATCC), RPMI-1640 medium and Ham’s F12 Medium
(Sigma–Aldrich, St. Louis, MO) with 10% fetal bovine serum
(ATCC). AlexaFluor 488 Protein Labeling kit was purchased
from Invitrogen to label bovine serum albumin (BSA),
BoNT/A, BoNT/A Complex, and NAPs. Other materials and
reagents include: Glass chamber slides (Lab-Tek II chamber
slide w/cover, Nalge Nunc International, Naperville, IL). 4%
Para-formaldehyde (Sigma–Aldrich, St. Louis, MO). Vecta-
Mount permanent mounting medium (Vector Laboratories,
Inc. Burlingame, CA). miRNeasy Mini Kit (Qiagen). Bio-Plex
Precision Pro Human Cytokine Assays (27-plex human
group I cytokine plus MIG) (Bio-Rad Laboratories, Hercules,
CA).
2.2. Cell culture and treatments
All the human neuronal and non-neuronal cell lines
were grown andmaintained as recommended by ATCC. The
SH-SY5Y cell line was derived from human brain neuro-
blastoma (Ross et al., 1983). Cells weremaintainedwith 10%
FBS in 5% CO2/humidiﬁed air at 37 C. SH-SY5Y cells grew as
a mixture of ﬂoating and adherent cells. The base growth
medium was 1:1 mixture of ATCC-formulated Eagle’s
Minimum Essential Medium and F12 Medium. To complete
the growthmedium fetal bovine serumwas added to a ﬁnal
concentration of 10%. The TIB-152 cell line is a mutant of
Jurkat (Weiss et al., 1984), and originates from acute T cell
leukemia by Schneider (Schneider et al., 1977). The TIB-152
cells are grown in suspension culture and the base medium
for this cell line was ATCC-formulated RPMI-1640 Medium.
To make the complete growth medium, 10% of fetal bovine
serumwas added to the base medium. RMS13 cell line was
established from cells from the bonemarrow of a child with
rhabdomyosarcoma (Oliner et al., 1992). The base medium
for RMI13 cell line was ATCC-formulated RPMI-1640 Me-
dium. To make the complete growth medium, fetal bovine
serum was added to a ﬁnal concentration of 10%. Human
skin ﬁbroblast cell line (Detroit 551) was from normal
human skin and had a ﬁnite lifespan of about 25 serial
passages from the tissue of origin (Sugarman et al., 1985).
SH-SY5Y, RMS13, and Detroit 551 were all adhesion
cells. These cells were seeded at a density of 2  105 cells/
well in 4-chamber glass chamber slides and grew for 2 days
before treatment with serum-free media containing 5 nM
of BoNT/A, BoNT/A complex, or NAPs proteins. 5 nM of BSA
in serum-free media was utilized as control culture. TIB-
152 were suspension cells, the following procedure from
L. Wang et al. / Toxicon 82 (2014) 52–6054McFeewas used for handling the cells with revision (McFee
et al., 1997): TIB 152 cell pellet was obtained fromT75 ﬂasks
by centrifugation (2500 rpm for 5 min). The cell density
was approximately 2  106 cells/ml. Cells were re-
suspended in serum-free media with 5 nM of BoNT/A
complexing proteins.
2.3. Cell binding by ﬂuorescence microscopy
BoNT/A, BoNT/A complex, and NAPs were labeled with
AlexaFluor 488 Protein Labeling kit (Invitrogen) accord-
ing to the manufacturer’s protocol. Labeled proteins were
puriﬁed from Sephadex G-25 column and eluted with
PBS buffer, pH 7.4. All labeled proteins were mixed with
20% glycerol and stored at 80 C for future use. For
adhesion cell lines, neuroblastoma SH-SY5Y cells, skeletal
muscle RMS13 cells, and skin ﬁbroblast Detroit 551 cells,
cells were seeded in 4-chamber glass chamber slides at a
density of 2  105 cells/well. Cells were grown to
conﬂuence then incubated with serum-free media con-
taining 5 nM of AlexaFluor 488 labeled BoNT/A, BoNT/A
complex, or NAPs proteins for 1 h in a 37 C humidiﬁed
incubator with 5% CO2. Medium was removed from
chamber slides, and then the cells were washed 3 times
with Hank’s balanced salt solution (HBSS). Cells were
then ﬁxed with 4% para-formaldehyde in PBS for 15 min
and were washed again with HBSS three times. The sides
of the slides were pulled off and cells were mounted withFig. 1. Fluorescent images showing binding of BoNT/A and its associated proteins to
images for cells treated with Alexaﬂuor 488 labeled BoNT/A (Panel B), with Alexaﬂ
NAPs (Panel D). All treatments were performed at 37 C for 1 h. Fluorescent imageone drop of VectaMount and covered with large cover
slip. Nail polish was used to seal the sides. Slides were
stored at 4 C in foil and observed under ﬂuorescence
microscope (Zeiss Axiovert microscope with X-Cite
120Q excitation light source). For lymphoblast TIB-152
Jurkat cells, the suspension cell line, cells were washed
twice with HBSS by centrifugation to remove free dye.
Cells were re-suspended in 4% Paraformaldehyde for
10 min at room temperature, and were then observed for
labeled protein binding under the ﬂuorescence micro-
scope with a hemocytometer which provided an even
monolayer of TIB-152 cells.
2.4. Cytokine multiplex ELISA
SH-SY5Y cells were seeded in 24-well plates with
approximately 1107 cells/well. Cells were incubated with
serum-free media containing 5 nM of BoNT/A, BoNT/A
complex, or NAPs, or for control, 5 nM BSA for 48 h. Su-
pernatants were collected and centrifuged at 13,300 rpm
with an Eppendorf MiniSpin Plus microcentrifuge for
10 min at 4 C to clear the precipitate and stored at 80 C
before being used for quantiﬁcation of secreted cytokines
and chemokines. The BioPlex 200 system was utilized for
the analysis of Bio-Rad 27-plex human group I cytokine
plus MIG. Concentrations of the following inﬂammatory
cytokines were determined: IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin,SH-SY5Y human neuroblastoma cells. Bright ﬁeld (Panel A) and ﬂuorescent
uor 488 labeled BoNT/A complex (Panel C), and with Alexaﬂuor 488 labeled
s were taken using Zeiss Axio ﬂuorescence microscope. Scale bar: 50 mm.
L. Wang et al. / Toxicon 82 (2014) 52–60 55Basic FGF, G-CSF, GM-CSF, IFN-g, IP-10, MCP-1, MIP-1a,
MIP-1b, PDGF-BB, RANTES, TNF-a, VEGF, and MIG. The
BioPlex assay (Bio-Rad) was performed according to the
manufacturer’s directions.
3. Results
BoNT/A alone, the complete BoNT/A complex, and the
NAPs alone, all bind to SH-SY5Y human neuroblastoma
cells (Fig. 1). The complete BoNT/A complex and the NAPs
also bind to TIB-152 human lymphoblasts, RMS13 human
skeletal muscle cells, and Detroit 551 human ﬁbroblasts, in
addition to the neuronal SH-SY5Y cells (Figs. 2–4). More-
over, no binding to these three non-neuronal cell lines was
observed with pure BoNT/A (Figs. 2–4). Alexaﬂuor 488
labeled BSA as the control culture did not bind to any of
these cell lines (data not shown). Our binding data for pure
BoNT/A conﬁrmed previously published research in which
the puriﬁed BoNT/A bound to cell lines of neuronal origin,
but not to those of non-neuronal origin (Kurokawa et al.,
1987). But it has not been reported before that in addi-
tion binding to human neuronal cells, both BoNT/A com-
plex and NAPs can also bind to non-neuronal cells such as
lymphoblasts, skeletal muscle cells, and ﬁbroblasts.
Although BoNT/A in its puriﬁed and complex forms all
bind to SH-SY5Y, the intracellular responses of the SH-SY5Y
cells to these BoNT/A components have not been well
studied. Among all the 28 human inﬂammatory cytokinesFig. 2. Fluorescent images showing binding of BoNT/A and its associated proteins
images for cells treated with Alexaﬂuor 488 labeled BoNT/A (Panel B), with Alexaﬂ
NAPs (Panel D). All treatments were performed at 37 C for 1 h. Fluorescent imagestested, there were three categories of cytokine release re-
sponses: (1) no detectable release, (2) release but no sig-
niﬁcant differences between BoNT/A, BoNT/A complex or
NAPs treatment, and (3) signiﬁcantly different release
induced by BoNT/A, BoNT/A complex or NAPs.
The release of the following thirteen cytokines was
below the limit of detection after exposure to different
components of BoNT/A associated proteins: IL-1b, MIG, IL-
1ra, IL-2, IL-5, IL-17, Eotaxin, basic FGF, G-CSF, GM-CSF, MIP-
1a, MIP-1b, and PDFF-BB (Supplementary Table S1). For the
following seven cytokines positive releases were detected,
but there were no signiﬁcant changes after the treatment
with BoNT/A, BoNT/A complex, or NAPs: IL-4, IL-7, IL-9, IL-
10, IL-12, IL-13, and IFN-g (Table S1).
The cytokines which were signiﬁcantly induced by
different components of BoNT/A and its associated proteins
are listed in Table 1. Pure 150 kDa BoNT/A did not signiﬁ-
cantly increase the release of any inﬂammatory cytokines
from SH-SY5Y cells, compared to BSA control. Exposure to
NAPs or BoNT/A complex, however, increased the release of
multiple inﬂammatory cytokines. The release of IL-6, MCP-
1, and VEGF were all signiﬁcantly increased after exposure
to BoNT/A complex and NAPs compared with control. In
addition, BoNT/A complex induced a signiﬁcant increase of
MCP-1 release compared with NAPs. BoNT/A complex, but
not NAPs or BoNT/A, also induced dramatic increase in IP-
10, IL-8, TNF-a, and RANTES compared with the control.
These results suggest the possibility of NAPs mayto TIB 152 human lymphoblasts cells. Bright ﬁeld (Panel A) and ﬂuorescent
uor 488 labeled BoNT/A complex (Panel C), and with Alexaﬂuor 488 labeled
were taken using Zeiss Axiovert ﬂuorescence microscope. Scale bar: 50 mm.
Fig. 3. Fluorescent images showing binding of BoNT/A and its associated proteins to RMS13 human skeletal muscle cells. Bright ﬁeld (Panel A) and ﬂuorescent
images for cells treated with Alexaﬂuor 488 labeled BoNT/A (Panel B), with Alexaﬂuor 488 labeled BoNT/A complex (Panel C), and with Alexaﬂuor 488 labeled
NAPs (Panel D). All treatments were performed at 37 C for 1 h. Fluorescent images were taken using Zeiss Axiovert ﬂuorescence microscope. Scale bar: 50 mm.
L. Wang et al. / Toxicon 82 (2014) 52–6056contribute to local and systemic inﬂammatory process after
the administration of NAPs-containing BoNT/A drugs in
patients.
4. Discussion
Over ﬁve million patients are being treated with botu-
linum neurotoxins globally (Singh et al., 2010), and because
of the safety concerns of this being the most toxic sub-
stance known tomankind, the United States Food and Drug
Administration (US FDA) has designated all botulinum
neurotoxin based drugs for black box label (Kuehn, 2009).
There have been reports of side effects such as cognition
issues and ﬂu-like symptoms from BoNT-based therapeu-
tics (Alam et al., 2002; Costa et al., 2005; Cote et al., 2005),
with little knowledge of their causes. Dissecting biochem-
ical effects of each component in active pharmaceutical
agent (APA) in BoNT drug products is the ﬁrst step towards
developing a comprehensive understanding of these ef-
fects. Since BoNT APA in commercial products contain the
BoNT and the NAPs, effects of these two components need
to be examined.
A differential binding of BoNT/A complexing proteins to
neuronal and nonneuronal cells has not been reported
previously. Our data suggest that pure BoNT/A binds spe-
ciﬁcally to neuronal cells, whereas NAPs bind to neuronal
cells as well as, to several non-neuronal cell types. This
observation suggests that NAPs may not be just a passive
group of associated proteins of BoNT/A complex, ratherthey at least bind to cells in injected tissues. Previous
studies have demonstrated that hemagglutinin (HA) pro-
teins, which are important components in the BoNT/A
complex, are important for carbohydrate recognition and
can bind to oligosaccharides on erythrocytes through HA-
33 (Arndt et al., 2005; Fujinaga et al., 2000; Inoue et al.,
2001). A similar mechanism is likely to be involved,
although a report had implicated HA-33 binding to one of
the known receptors of BoNT/A (Zhou et al., 2005). The
signs and symptoms of ﬂu symptoms are ordinarily asso-
ciated with inﬂuenza virus infection (Puzelli et al., 2009).
Previous research has shown that HA inﬂuences the
infectivity of type A inﬂuenza virus in dendritic cells (DC).
The DC cells play a key role in early phases of the immune
response, and subsequently as antigen-presenting cells
that activate the adaptive immune response (Hargadon
et al., 2011). In addition, our previous study demonstrated
that NAPs have stronger immunogenicity over that of pu-
riﬁed neurotoxin, thus having a higher potential of BoNT/
AC and its associated proteins to induce host immune
response (Kukreja et al., 2009). BoNT/A itself appears to be
directed to a given cell type through a speciﬁc set of gan-
gliosides and speciﬁc protein receptors. For example, recent
research reports have suggested that the same receptors on
neuronal and intestinal cells could drive distinct trafﬁcking
pathways for BoNT (Humeau et al., 2000).
A relevant question is what the implications of the
binding of BoNTor NAPs to a given type of cells are? BoNT/A
binding results in internalization and translocation into the
Fig. 4. Fluorescent images showing binding of BoNT/A and its associated proteins to Detroit 551 human ﬁbroblasts cells. Bright ﬁeld (Panel A) and ﬂuorescent
images for treated with Alexaﬂuor 488 labeled BoNT/A (Panel B), with Alexaﬂuor 488 labeled BoNT/A complex (Panel C), and with Alexaﬂuor 488 labeled NAPs
(Panel D). All treatments were performed at 37 C for 1 h. Fluorescent images were taken using Zeiss Axiovert ﬂuorescence microscope. Scale bar: 50 mm.
L. Wang et al. / Toxicon 82 (2014) 52–60 57cytosol where it cleaves SNAP-25 leading to blockage of
neurotransmitter release (Sharma et al., 2006; Poulain
et al., 2009). We were interested in what other biochem-
ical or physiological response caused by the presence of
toxin inside the neuronal cells. Previously we had tested
effect on BoNT/A on apoptosis of neuronal cells (Kumar
et al., 2012). In this work, we examined cytokine
response, and concluded that pure BoNT/A caused virtually
no cytokine response after 48 h of incubation (Table 1).
However, BoNT/A complex and NAPs exerted substantial
yet selective cytokine response, suggesting that NAPs
binding, and possible entry into the cell has signiﬁcant host
response. It is, however, notable that NAPs by themselves
do not exert as much inﬂuence as the BoNT/A complex,
except for IL-6 which showed equal response (Table 1).
MCP-1 and VEGF were two other cytokines which were
induced by NAPs alone, albeit not as strongly as BoNT/A
complex. BoNT/A complex and NAPs both contain associ-
ated proteins for BoNT/A. However, exposition to BoNT/A
complex, but not to NAPs, resulted in signiﬁcant increase of
IP-10, IL-8, IL-15, TNF-a, and RANTES. For the current
research, cytokine release was examined after 48 h of in-
cubation. The kinetics of cytokine release have been stud-
ied for 24 h to up to one week in lymphocyte (Arva and
Andersson, 1999) and kinetics of TNF, IL-6, and IL-8 gene
expression after inﬂammatory stimuli have been shown to
have multiple peak at 2–4 h and 24 h (DeForge and Remick,
1991). Although no cytokine release was induced by pure
BoNT/A in the current experimental setting, furtherinvestigation with different incubation time on complex
patterns of cytokine gene expression and production with
pure BoNT/A as well as other components of BoNT/A
complex is needed.
Higher effect of BoNT/A complex could arise from one or
more of the following reasons. One, there is higher level of
binding of the BoNT/A in the BoNT/A complex allowing
more NAPs to enter the cell. Two, interaction between
BoNT/A and NAPs introduce conformational changes which
are more critical for triggering cytokine response. Three,
there is a physiological link between the effects of BoNT/A
and NAPs intracellularly, leading to synergistic host cell
response.
A previous study on the co-culture of microglia and SH-
SY5Y cells has shown the expression of IL-6, IL-8, and MCP-
1 with borrelia burgdorferi stimulation, a spirochete that
causes lyme disease, and it is known to potently induce the
production of inﬂammatory mediators in a variety of cells
(Myers et al., 2009). Release of MCP-1 from SH-SY5Y has
also been reported during the neuroinﬂammation process
(Mitchell et al., 2009).
Physiological role of cytokine release in neuronal cells
can be manifold. The presence and activity of pro-
inﬂammatory cytokines IL-1b and TNF-a were ﬁrst re-
ported in human and rat brain a decade ago (Breder et al.,
1988; Plata-Salaman et al., 1988). Cytokine release studies
enable us to identify cytokines that are produced specif-
ically upon BoNT/A, its complex, or NAPs stimulation. The
SH-SY5Y cell line has been proven to be a useful in vitro
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L. Wang et al. / Toxicon 82 (2014) 52–6058model for TNF production from neurons and the regulation
of that production by alpha2-adrenergic receptor activation
(Renauld and Spengler, 2002). Additionally, TNF-a has been
shown not only play the critical roles in pathological
development and inﬂammatory induction, but on modu-
lating cell proliferation of neural progenitors in CNS
inﬂammation (Downen et al., 1999;Wu et al., 2000). A TNF-
a increase of more than 20-fold in BoNT/A complex treated
SH-SY5Y cells compared to BoNT/A or NAPs indicates that
BoNT/A complex triggered the release of the cytokine and
might account for the proinﬂammatory response of BoNT/
A. Neuron-derived TNF-a may maintain the activity of
neurons by sustaining physiologic levels of neurotrans-
mitter release through regulation of adrenergic autor-
eceptor activity (Ignatowski et al., 1997). Flu like symptoms
have been reported in between 1.7 and 20% of patients
treated with various preparations of BoNT/A (Baizabal-
Carvallo et al., 2011). It has been reported that neurons
and glial cells produce cytokines in cell culture, in partic-
ular after addition of inﬂammatory stimuli (Schobitz et al.,
1994). A recent published study evaluated blood cytokines
of patients following treatment with BoNT and discovered
that inﬂammatory cytokines are increased inmany patients
following BoNT injection (Baizabal-Carvallo et al., 2013),
although clear role of NAPs was not deciphered.
Our study suggested that the observed ﬂu-like symp-
toms after BoNT/A application may also be the result of
inﬂammation resulting from the inﬂammatory mediators
released in response to some components in the BoNT/A
complexing proteins. Due to the fact that in the current
study, we utilized laboratory grade pure BoNT/A, BoNT/A
Complex, and NAPs instead of commercially available
products, and the in vitro concentrations of BoNT/A and
associated protein in the current study are higher than the
therapeutical use, further research needs to be done for this
aspect. For the comparison of current commercially avail-
able BoNT/A products, the primary challenge is that the
lack of standardized measurement. The units of different
BoNT/A products are not interchangeable due to the dif-
ferences of LD50 protocols in house (Sesardic, 2010). We
plan to compare the host response of cells to different
currently available products and will need to determine a
relative equipotency point for these agents during the
treatment. It is very important to utilize the concentration
in the range of nM in cellular model to avoid false negative
results. We will also include fM to pM concentration range,
which is therapeutic dose, to facilitate our understanding of
clinical observations.
It is concluded that BoNT/A in the complex form with
the presence of NAPs protein induced signiﬁcant inﬂam-
matory cytokine release. The presence of NAPs has also
been shown to accentuate the immune response to the
BoNT/A injections (Siatkowski et al., 1993; Goschel et al.,
1997). As the presence of associated proteins within the
therapeutic formulation of BoNT/A complex increases the
protein load, and may accentuate the immune response or
inﬂammatory process, further experiments to investigate
effects of BoNT/A components arewarranted. It may help to
clarify different physical effects caused by BoNT/A in its
puriﬁed or complex forms. Clearly understanding the
intracellular signaling pathways and the mechanism of the
L. Wang et al. / Toxicon 82 (2014) 52–60 59inﬂammatory effects of BoNT/A and its associated proteins
will reveal the crucial role for each components in both
physiologic as well as in pathologic conditions of neurons.Acknowledgments
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